Stock Market Reviews

CDTX (Cidara Therapeutics, Inc.) News

Get the latest news, insights, and market updates on CDTX (Cidara Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Merck's Subdued 2026 Outlook: What it Means After Q4 Results?
  MRK posts conservative 2026 sales and EPS outlook, given acquisition charges. Keytruda, Animal Health and new drug launches are expected to drive 2026 growth.
  Feb 6, 2026 - $CDTX
• Merck Issues Full-Year Outlook Below Expectations Despite Fourth-Quarter Beat
  Merck (MRK) provided a full-year outlook below Wall Street's estimates on Tuesday, overshadowing the
  Feb 3, 2026 - $CDTX
• Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
  RAHWAY, N.J., February 03, 2026--Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results
  Feb 3, 2026 - $CDTX
• Dow Jones Giant Merck Crushes Fourth-Quarter Views And Shakes Off Guidance Scare
  Merck quashed fourth-quarter expectations Tuesday, but the Dow Jones health giant issued lackluster expectations for 2026.
  Feb 3, 2026 - $CDTX
• Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
  Merck heads into Q4 earnings with strong Keytruda demand and new product launches, but declining estimates and M&A costs cloud the near-term outlook.
  Jan 30, 2026 - $CDTX
• Merck to Complete Acquisition of Cidara Therapeutics
  RAHWAY, N.J., January 07, 2026--Merck to Complete Acquisition of Cidara Therapeutics
  Jan 7, 2026 - $CDTX
• Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
  HighVista Strategies initiated a position in Cidara Therapeutics, buying 70,904 shares valued at $6.79 million. The position represents 1.66% of 13F reportable assets under management (AUM). The stake represents 1.66% of AUM, which places it outside the fund's top five holdings.
  Jan 2, 2026 - $CDTX
• Cidara Therapeutics (CDTX) Rockets 722% in 2025 on Merck $9.2-Billion Merger
  We recently published 10 Market Stars Behind Millionaire-Making in 2025. Cidara Therapeutics Inc. (NASDAQ:CDTX) is one of the top performers. Cidara Therapeutics climbed by 721.76 percent in 2025, primarily bolstered by its looming merger with Merck for $9.2 billion. In an announcement last November, Cidara Therapeutics Inc. (NASDAQ:CDTX) said that it signed a definitive agreement […]
  Jan 2, 2026 - $CDTX
• Cidara Therapeutics (CDTX): Assessing Valuation After a 200% Three‑Month Share Price Surge
  Cidara Therapeutics (CDTX) has quietly turned into a strong performer, with the stock up more than 200% over the past 3 months. This invites a closer look at what investors might be pricing in. See our latest analysis for Cidara Therapeutics. That explosive 90 day share price return of roughly 221 percent sits on top of an even more dramatic year, with total shareholder returns near 879 percent. This signals powerful momentum as investors reassess Cidara Therapeutics growth prospects and risk...
  Dec 18, 2025 - $CDTX
• Merck Poised for Mid-Single-Digit Revenue Growth in Fiscal 2026, BofA Says
  Merck (MRK) is expected to deliver mid-single-digit revenue growth in fiscal 2026 driven primarily b
  Dec 15, 2025 - $CDTX